BSXvsCI
Boston Scientific CorpvsCigna Group. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Boston Scientific Corp
$64.87
-29.93%
Cigna Group
$279.72
+1.31%
60-day price, rebased to 100
Round-by-round
Valuation upside
-27.90% vs +961.30% to DCF fair value
Balance-sheet strength
Altman Z 3.90 vs 2.53
Fundamental quality
Piotroski 9.00 vs 7.00 (of 9)
Growth + margins
Rule-of-40 36.80 vs 15.50
60-day momentum
-30.83% vs +2.05% price return
Market-cap liquidity
$91.9B vs $71.2B
Verdict
Across6categories,BSXtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onBSXorCI
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.